Clinical Trial

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

Study acronym: ESR-23-22182
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a randomized Phase II study of intermittent versus continuous venetoclax therapy with Acalabrutinib in previously untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-02.
Status change: Not Yet Recruiting → Recruiting 2026-01-02
Trial Details
NCT Number NCT07014917
Lead Sponsor Zulfa Omer
Conditions Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL Variant
Enrollment 62 participants
Start Date 2025-12-05
Primary Completion 2028-06-05 (estimated)
Study Completion 2032-06-05 (estimated)
Updated on ClinicalTrials.gov 2026-01-06